Skip to content

Novavax Files for U.K. Approval of Covid Protein Shot

  • Vaccine has shown 96% efficacy against original Covid strain
  • Drugmaker will apply for U.S. authorization by end of year
     
Photographer: Angel Garcia/Bloomberg
Corrected

Follow us at @BloombergUK for the latest news and analysis.

Novavax Inc. applied for U.K. authorization of its Covid-19 vaccine, the first submission for a protein-based shot against the disease in Europe.